What We're Reading: Page 96
Industry reads hand-picked by our editors
Nov 17, 2022
Nov 16, 2022
Nov 15, 2022
-
Wired
The $6 Billion Shot at Making New Antibiotics—Before the Old Ones Fail
-
Bloomberg
Soaring Infant Lung Illnesses Spur Race for Prevention
-
The Wall Street Journal
Walmart to Pay $3.1 Billion to Settle Opioid Lawsuits
-
Kaiser Health News
Thousands of Experts Hired to Aid Public Health Departments Are Losing Their Jobs
Nov 14, 2022
-
Reuters
U.S. seeks 15 years for Elizabeth Holmes over Theranos fraud
-
Bloomberg
Biotech CEO Mark McKenna Explains What Drug Dealmaking Trends to Watch
-
The Financial Times
Bristol Myers Squibb warns UK medicines levy threatens investment
-
Wired
This Personalized Crispr Therapy Is Designed to Attack Tumors
Nov 11, 2022
-
Science
‘I’m nauseated’: Alzheimer’s whistleblower finds possible misconduct by his mentor in their papers
-
STAT
Biogen’s new CEO, clear-eyed about company’s challenges, prepares to take the reins
-
BioCentury
AstraZeneca may defer U.S. cancer drug launches in response to IRA
-
Endpoints News
Teva wins $175M settlement after jury orders Eli Lilly to pay up on patent infringement suit
Nov 10, 2022
-
The New York Times
The Disease Took Zara, Then Sara. Could Ayla Be Saved?
-
Financial Times
Psychedelics and business could make for a bad trip
-
Reuters
U.S. FDA panel votes against Veru’s COVID-19 pill
Nov 09, 2022
-
Financial Times
Patent wars: Moderna’s battle for the spoils of Covid vaccines
-
The Boston Globe
Pfizer dominates the COVID drug market. This Watertown biotech wants to change that.
-
FierceBiotech
FDA panel delivers mixed verdict on AstraZeneca’s asthma drug
-
Bloomberg
Pfizer to Enforce 2-3 Days of Weekly Office Work in January
Previous
